Impact of 6 weeks of treatment with low-dose metformin and atorvastatin on glucose-induced changes of endothelial function in adults with newly diagnosed type 2 diabetes mellitus: A single-blind study

Clinical Therapeutics

Volumn 32, Issue 10, 2010, Pages 1720-1728

  Tousoulis, Dimitris ^a   Koniari, Katerina ^a   Antoniades, Charalambos ^a   Miliou, Antigoni ^a   Noutsou, Marina ^a   Nikolopoulou, Aggeliki ^a   Papageorgiou, Nikolaos ^a   Marinou, Kyriakoula ^a   Stefanadi, Elli ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Atorvastatin; Diabetes; Endothelial dysfunction; Metformin; Statins

Indexed keywords

ATORVASTATIN; CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LIPOPROTEIN; METFORMIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; GLUCOSE TOLERANCE TEST; HUMAN; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ATHEROSCLEROSIS; BLOOD FLOW VELOCITY; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; GLUCOSE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; METFORMIN; MIDDLE AGED; PLETHYSMOGRAPHY; PYRROLES; SINGLE-BLIND METHOD; TREATMENT OUTCOME; VASODILATION;

EID: 78650599486     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.09.007     Document Type: Article

References (39)

1. Potenza MA, Gagliardi S, Nacci C, et al. Endothelial dysfunction in diabetes: From mechanisms to therapeutic targets. Curr Med Chem. 2009, 16:94-112.
2. Okon EB, Chung AW, Zhang H, et al. Hyperglycemia and hyperlipidemia are associated with endothelial dysfunction during the development of type 2 diabetes. Can J Physiol Pharmacol. 2007, 85:562-567.
3. Su Y, Liu XM, Sun YM, et al. Endothelial dysfunction in impaired fasting glycemia, impaired glucose tolerance, and type 2 diabetes mellitus. Am J Cardiol. 2008, 102:497-498.
4. Settergren M, Böhm F, Malmström RE, et al. L-arginine and tetrahydrobiopterin protects against ischemia/ reperfusion-induced endothelial dysfunction in patients with type 2 diabetes mellitus and coronary artery disease. Atherosclerosis. 2009, 204:73-78.
5. Antoniades C, Tousoulis D, Tountas C, et al. Vascular endothelium and inflammatory process, in patients with combined type 2 diabetes mellitus and coronary atherosclerosis: The effects of vitamin C. Diabet Med. 2004, 21:552-558.
6. Calles-Escandon J, Cipolla M Diabetes and endothelial dysfunction: A clinical perspective. Endocr Rev. 2001, 22:36-52.
7. Begum N, Song Y, Rienzie J, Ragolia L Vascular smooth muscle cell growth and insulin regulation of mitogenactivated protein kinase in hypertension. Am J Physiol. 1998, 275:C42-C49.
8. Goalstone ML, Natarajan R, Standley PR, et al. Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells. Endocrinology. 1998, 139:4067-4072.
9. Schalkwijk CG, Stehouwer CD Vascular complications in diabetes mellitus: The role of endothelial dysfunction. Clin Sci (Lond). 2005, 109:143-159.
10. Rizzoni D, Porteri E, Guelfi D, et al. Endothelial dysfunc- tion in small resistance arteries of patients with non-insulin- dependent diabetes mellitus. J Hypertens. 2001, 19:913-919.
11. Tousoulis D, Antoniades C, Stefanadis C Evaluating endothelial function in humans: A guide to invasive and non-invasive techniques. Heart. 2005, 91:553-558.
12. Mather KJ, Verma S, Anderson TJ Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001, 37:1344-1350.
13. Skrha J, Prázný M, Hilgertová J, et al. Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus. Eur J Clin Pharmacol. 2007, 63:1107-1114.
14. Isoda K, Young JL, Zirlik A, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol. 2006, 26:611-617.
15. Hattori Y, Suzuki K, Hattori S, Kasai K Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension. 2006, 47:1183-1188.
16. Stocker DJ, Taylor AJ, Langley RW, et al. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J. 2007, 153(445):e1-e6.
17. Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care. 2004, 27:1349-1357.
18. Reaven GM, Chen YD, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest. 1993, 92:141-146.
19. Antoniades C, Tousoulis D, Marinou K, et al. Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis. Clin Cardiol. 2007, 30:295-300.
20. Moon YS, Kashyap ML Pharmacologic treatment of type 2 diabetic dyslipidemia. Pharmacotherapy. 2004, 24:1692-1713.
21. Velussi M, Cernigoi AM, Tortul C, Merni M Atorvastatin for the management of type 2 diabetic patients with dyslipidemia. A mid-term (9 months) treatment experience. Diabetes Nutr Metab. 1999, 12:407-412.
22. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1999, 159:2661-2667.
23. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet. 2004, 364:685-696. CARDS Investigators.
24. Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: A meta-analysis. Diabetes Care. 2009, 32:1924-1929.
25. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979, 28:1039-1057. National Diabetes Data Group.
26. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 1994, 89:2519-2524.
27. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995, 332:481-487.
28. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995, 332:488-493.
29. van Venrooij FV, van de Ree MA, Bots ML, et al. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes. The Diabetes Atorvastatin Lipid Intervention (DALI) Study: A randomized, double-blind, placebo-controlled trial. Diabetes Care. 2002, 25:1211-1216. DALI Study Group.
30. van de Ree M, Huisman M, de Man FH, et al. Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc Res. 2001, 52:299-305.
31. Tan KC, Chow WS, Tam SC, et al. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2002, 87:563-568.
32. Clarke WL, Cox D, Gonder-Frederick LA, et al. Evaluating clinical accuracy of systems for self-monitoring of blood glucose. Diabetes Care. 1987, 10:622-628.
33. Belcher G, Lambert C, Edwards G, et al. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2005, 70:53-62.
34. Bakker-Arkema RG, Nawrocki JW, Black DM Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. Atherosclerosis. 2000, 149:123-129.
35. Field A Discovering Statistics Using SPSS: (and Sex, Drugs and Rock 'n' Roll) 2009, Sage Publications, London, UK; Thousand Oaks, Calif. 2nd ed.
36. Tousoulis D, Antoniades C, Katsi V, et al. The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level. Int J Cardiol. 2006, 109:48-52.
37. Laufs U, Fata VL, Liao JK Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 1997, 272:31725-31729.
38. Laufs U, La Fata V, Plutzky J, Liao JK Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998, 97:1129-1135.
39. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008, 359:2195-2207. JUPITER Study Group.